Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PTAFR | P25105 | 8/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456241 | 1.00 | TDP2 (0.45) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL728503 | 0.88 | CYP2A6 (0.48) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL2171651 | 0.88 | CYP2A6 (0.44) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL29412464 | 0.88 | CYP2A6 (0.48) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL4095527 | 0.84 | HRH1 (0.49) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL7255792 | 0.76 | CES1 (0.61) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL8118609 | 0.76 | MAOA (0.46) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL5235878 | 0.75 | CYP1A2 (0.48) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL4912110 | 0.75 | TSHR (0.43) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL730635 | 0.74 | HRH1 (0.58) | TDP2NSD2ABL1PLCG1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| CN-119798162-A | Preparation method of ternary ring on 5, 6-dihydro-cyclopenta-pyridin-7-one compound | 浙江瑞博制药有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-118908957-A | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-112979650-B | Organic compound and organic electroluminescent device containing the same | 北京鼎材科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-114222737-B | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118307504-A | Orange ketone derivative or analogue, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-07-09 | — | — | CN | disclosed |
| CN-115960109-B | Preparation and application of condensed ring SHP2 phosphatase inhibitor | 药雅科技(上海)有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4244224-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022237676-A1 | PREPARATION AND APPLICATION OF SHP2 PHOSPHATASE INHIBITOR | 药雅科技(上海)有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2022104348-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-19 | — | — | WO | disclosed |
| EP-3976597-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | Janssen Pharmaceutica NV (BE) | 2022-04-06 | — | — | EP | disclosed |
| CN-110964018-B | Indole derivative and application thereof | 华侨大学 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | TDP2 1801/4885NSD2 198/4885ABL1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.